What’s at stake?
Maintaining normal blood volume or “euvolemia” is critical to ensuring vital organs are adequately perfused or properly oxygenated. Levels of total blood volume as well as the primary components of blood, plasma and red blood cells, can be too high or too low vary in a broad range of acute and chronic medical conditions, including congestive heart failure, blood loss due to trauma or surgical procedures, hypertension, renal failure, syncope, and chronic fatigue syndrome. Measuring blood volume accurately and directly enables more precise diagnosis and treatment of blood volume and red blood cell abnormalities.
Indirect measures offer low clinical utility as indicators of true TBV & RBCV
In the absence of the direct BVA-100 test, physicians predominantly rely on clinical assessment and a range of surrogate measures for blood volume (i.e. hemoglobin, hematocrit, central venous pressure, levels of brain natriuretic peptide, etc.) to estimate patient blood volume. A multitude of studies have shown these indirect tests to lack specificity and sensitivity compared to the BVA-100. Treatment goals and strategies are a high-stakes guessing game without accurate knowledge of both the patient’s actual and ideal total blood volume.
“The BVA is a method that provides an accurate measure of actual blood volume and gives researchers and clinicians the opportunity to measure the blood volume as opposed to estimate it. Our research essentially shows that reliance on surrogate markers of volume could be problematic. This provides an avenue to better understand our approach to patients with heart failure.”
Marat Fudim, M.D. – Duke University
Heterogeneity in TBV & RBCV status is common
Not every patient case is the same. Patients with the identical clinical symptoms often have different etiologies and intravascular blood volume. The BVA-100 reveals this variability permitting precise individualized therapeutic strategies instead of a “one-size-fits-all” approach.
“The extent, composition, and distribution of volume overload in decompensated heart failure are highly variable, and this variability needs to be taken into account in the approach to individualized therapy.”
Wayne L. Miller, M.D. – Mayo Clinic
Hospitals and clinicians struggle with readmissions, mortality and wasted resources. The BVA-100 provides clinicians with accurate, actionable data to optimize treatment plans and individualize care improving outcomes and reducing duration and cost of care.